SCHEMBL21616144

SCHEMBL21616144

Cc1c(C=O)sc2c1C(c1ccc(Cl)cc1)=N[C@@H](C)c1nnc(C)n1-2

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 20/20 0.60
DNER Q8NFT8 2/20 0.59
ADORA3 P0DMS8 1/20 0.57
TSPO P30536 1/20 0.57
BRDT Q58F21 6/20 0.54
BRD2 P25440 5/20 0.54
BRD3 Q15059 3/20 0.54
CREBBP Q92793 2/20 0.54
HDAC3 O15379 1/20 0.54
JAK2 O60674 1/20 0.54
BRD1 O95696 1/20 0.54
CCL2 P13500 1/20 0.54
HDAC4 P56524 1/20 0.54
EP300 Q09472 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC2 Q92769 1/20 0.54
HDAC10 Q969S8 1/20 0.54
HDAC11 Q96DB2 1/20 0.54
HDAC8 Q9BY41 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23348815 1.00 BRD4 (0.60) BRD4DNERADORA3TSPOBRDT
SCHEMBL19986290 0.86 BRD4 (0.68) BRD4DNERADORA3TSPOBRDT
SCHEMBL16976612 0.86 BRD4 (0.68) BRD4DNERADORA3TSPOBRDT
SCHEMBL18463912 0.86 BRD4 (0.68) BRD4DNERADORA3TSPOBRDT
SCHEMBL3202033 0.85 BRD4 (0.82) BRD4DNERADORA3TSPOBRDT
SCHEMBL19453084 0.84 BRD4 (0.55) BRD4DNERADORA3TSPOBRDT
SCHEMBL2543303 0.83 BRD4 (0.60) BRD4DNERADORA3TSPOBRDT
SCHEMBL2543310 0.83 BRD4 (0.60) BRD4DNERADORA3TSPOBRDT
SCHEMBL23317926 0.83 BRD4 (0.83) BRD4DNERADORA3TSPOBRDT
SCHEMBL21616191 0.81 BRD4 (0.53) BRD4DNERADORA3TSPOBRDT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112543764-B Amide compound with BET proteolytic induction effect and medical application thereof 田边三菱制药株式会社 2024-05-10 CN disclosed
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-01-03 US disclosed
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-01-03 US disclosed
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2021-09-16 US disclosed
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2021-09-16 US disclosed
EP-3819305-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2021-05-12 EP disclosed
EP-3819305-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2021-05-12 EP disclosed
WO-2020009176-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF 田辺三菱製薬株式会社 2020-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof BET1, BRD4, PHKB BRD4 2/4885DNER 780/4885ADORA3 4629/4885
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF BET1, BRD4, PHKB BRD4 2/4885DNER 690/4885ADORA3 4656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.